Want to see GB:GENI full AI Analyst Report?
Top Page
GENinCode UK Ltd.
(LSE:GENI)
Select Model
Select Model
Rating:43Neutral
Price Target:
0.87 p
▼(-60.50% Downside)
Action:Upgraded
Date:06/09/26
The score is held down primarily by heavy ongoing losses, continued cash burn, and weakened equity, which collectively increase financial risk. Technicals also remain soft with the stock below major moving averages and muted momentum. Valuation provides limited support because earnings are negative and no dividend yield is available.
Positive Factors
Focused genomics diagnostics niche
GENinCode's product focus on genomic profiling and genetic tests for cardiovascular risk represents a specialized, clinically oriented business model. A clear clinical-use focus supports durable adoption by healthcare professionals and labs, enabling repeatable revenues and targeted commercialization.
Negative Factors
Deep and widening losses
Very large negative net margins and ongoing negative EBIT/EBITDA indicate the core business is not yet profitable and losses are structural at current scale. Continued deep losses erode capital, constrain strategic options, and make self-funded growth unlikely without external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused genomics diagnostics niche
GENinCode's product focus on genomic profiling and genetic tests for cardiovascular risk represents a specialized, clinically oriented business model. A clear clinical-use focus supports durable adoption by healthcare professionals and labs, enabling repeatable revenues and targeted commercialization.
Read all positive factors
GENinCode UK Ltd. (GENI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£7.00M
Dividend YieldN/A
Average Volume (3M)1.99M
Price to Earnings (P/E)―
Beta (1Y)-0.66
Revenue Growth13.88%
EPS Growth15.35%
CountryUK
Employees42
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.02
Shares Outstanding753,041,140
10 Day Avg. Volume166,671
30 Day Avg. Volume1,986,185
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)53.10
Price to Sales (P/S)2.14
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£4.70M
GENinCode UK Ltd. Business Overview & Revenue Model
Company Description
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technolo...
How the Company Makes Money
null...
GENinCode UK Ltd. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
35
Negative
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.08M | 2.70M | 2.16M | 1.43M | 1.15M |
| Gross Profit | 1.54M | 1.43M | 1.02M | 632.00K | 593.00K |
| EBITDA | -5.63M | -4.69M | -6.65M | -5.57M | -4.10M |
| Net Income | -5.71M | -4.43M | -7.02M | -5.56M | -4.14M |
Balance Sheet | |||||
| Total Assets | 2.38M | 2.66M | 4.19M | 11.80M | 15.21M |
| Cash, Cash Equivalents and Short-Term Investments | 895.00K | 1.17M | 2.53M | 9.75M | 14.56M |
| Total Debt | 146.00K | 234.00K | 299.00K | 354.00K | 0.00 |
| Total Liabilities | 2.25M | 1.54M | 2.90M | 3.90M | 1.49M |
| Stockholders Equity | 124.00K | 1.13M | 1.29M | 7.90M | 13.72M |
Cash Flow | |||||
| Free Cash Flow | -4.11M | -5.22M | -7.54M | -4.61M | -3.17M |
| Operating Cash Flow | -4.07M | -5.17M | -7.51M | -3.76M | -3.02M |
| Investing Cash Flow | -44.00K | 50.00K | 136.00K | -849.00K | -145.00K |
| Financing Cash Flow | 3.64M | 3.65M | -94.00K | -47.00K | 15.86M |
GENinCode UK Ltd. Technical Analysis
Negative
2.20
Price Trends
1.06
Negative
1.09
Negative
1.90
Negative
Market Momentum
-0.04
Negative
44.69
Neutral
67.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GENI, the sentiment is Negative. The current price of 2.2 is above the 20-day moving average (MA) of 0.97, above the 50-day MA of 1.06, and above the 200-day MA of 1.90, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 44.69 is Neutral, neither overbought nor oversold. The STOCH value of 67.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:GENI.
GENinCode UK Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £25.91M | -12.20 | -55.91% | ― | 40.37% | -13.70% | |
49 Neutral | £20.87M | -1.19 | -153.92% | ― | 65.60% | 74.84% | |
48 Neutral | £17.33M | -0.49 | -104.73% | ― | -52.80% | 23.22% | |
45 Neutral | £10.05M | -0.33 | 425.97% | ― | ― | ― | |
43 Neutral | £7.00M | -0.43 | -181.41% | ― | 13.88% | 15.35% | |
38 Underperform | £4.29M | -0.10 | -316.67% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:GENI
GENinCode UK Ltd.
0.93
-1.32
-58.67%
GB:CLBX
ANGLE plc
1.53
-5.23
-77.41%
GB:GDR
Genedrive
1.30
-0.08
-6.00%
GB:OBD
Oxford BioDynamics
0.10
-0.20
-66.67%
GB:RENX
Renalytix
2.30
-4.70
-67.14%
GB:ABDX
Abingdon Health PLC
10.25
3.25
46.43%
GENinCode UK Ltd. Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
GENinCode targets accelerated genetic testing scale-up as revenues rise and U.S. adoption grows
Positive
Jun 8, 2026
GENinCode reported a 14% rise in 2025 revenues to £3.1m, driven by volume growth in the U.S. and Europe and expanding adoption of its LIPID inCode and CARDIO inCode tests, despite NHS headwinds. Margins improved to 59%, though adjusted EBITDA...
Business Operations and StrategyFinancial Disclosures
GENinCode Sets June Dates to Present 2025 Audited Results to Market
Neutral
May 22, 2026
GENinCode Plc, a UK-based predictive genetics firm focused on cardiovascular disease and ovarian cancer, develops CE-marked molecular diagnostic tests that combine clinical algorithms and bioinformatics to assess patient risk. The company serves m...
Business Operations and StrategyExecutive/Board Changes
GENinCode Resets Share Option Plan to Align Incentives With Current Valuation
Neutral
May 7, 2026
GENinCode Plc has granted options over 83,847,292 new ordinary shares under its 2021 Share Option Plan to directors and employees, equivalent to 11.13% of its issued share capital, while cancelling 29,856,434 existing higher-priced options. The mo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.